Vimpat · DIN 02357623 · 100 mg · tablet
Limited Use, Reason for Use code 430 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 430 required
Write on scriptReason for Use code 430 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 430
Reason for Use code 430
As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND
Patients are under the care of a physician experienced in the treatment of epilepsy.
Note: Less costly anticonvulsant therapies may include the following:
Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Vimpat · DIN 02357623
Manufacturer: UCB Canada Inc.; listing date 2012-04-24
Health Canada: Marketed since 2010-10-21 · brand VIMPAT · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 100 MG · company Ucb canada inc · schedule Prescription
Ministry pays: $0.8750 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02357623)
Source record
DIN 02357623: Vimpat
Raw flags: sec12=Y, sec3=Y
Item: 281200149; group id 431; item number 1076; lccId 00221; manufacturer id UCB
Source form: Tab; strength: 100mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.5000; ministry $0.8750
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02357623
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84273
Interchangeable products
Ach-Lacosamide · DIN 02489295 · $0.8750
Auro-Lacosamide · DIN 02475340 · $0.8750
Jamp-Lacosamide · DIN 02488396 · $0.8750
Lacosamide · DIN 02512882 · $0.8750
Mint-Lacosamide · DIN 02490552 · $0.8750
NRA-Lacosamide · DIN 02499576 · $0.8750
Pharma-Lacosamide · DIN 02478218 · $0.8750
Sandoz Lacosamide · DIN 02474689 · $0.8750
Teva-Lacosamide · DIN 02472910 · $0.8750
ZDS-Lacosamide · DIN 02487810 · $0.8750
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02357623
Shortage record checked October 6, 2026